📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Sequenta

1.1 - Company Overview

Sequenta Logo

Sequenta

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical diagnostics and immune profiling tools based on a platform for understanding immune system status. Products include clonoSEQ for MRD detection and monitoring in multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; immunoSEQ for sequencing T- and B-cell receptors; T-Detect to identify recent or past infections, including COVID-19; and an Immune Medicine Platform mapping immune receptors to antigens.

Products and services

  • ClonoSEQ: A clinical diagnostic test that detects and longitudinally monitors minimal residual disease by sequencing in multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia
  • Immune Medicine Platform: A DNA-sequencing-driven platform that sequences and maps immune receptors to antigens, enabling development of diagnostics and therapeutics across diverse diseases
  • ImmunoSEQ: A research-grade profiling system that sequences T-cell and B-cell receptors to profile and monitor adaptive immune response dynamics

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Sequenta

Omniome Logo

Omniome

HQ: United States Website
  • Description: Provider of a proprietary DNA sequencing platform delivering high-accuracy short-read sequencing using Sequencing by Binding (SBB) chemistry. Offers the Onso hardware and software system; validated exome/panel sequencing; single-cell RNA-Seq solutions; and tools for cancer research and gene editing, with lower error rates than traditional sequencing by synthesis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Omniome company profile →
Agena Bioscience Logo

Agena Bioscience

HQ: United States Website
  • Description: Provider of molecular diagnostic genetic reagents and mass spectrometry-based analysis systems, including the MassARRAY System for high-throughput genetic analysis in pharmacogenomics, mutation profiling, liquid biopsy, and inherited disease testing; PGx panels and the VeriDose Core Panel; custom assay services; the Revolution Sample Prep System for cfDNA extraction; and the MassARRAY Insights reporting software network.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Agena Bioscience company profile →
NanoString Logo

NanoString

HQ: United States Website
  • Description: Provider of life science tools for basic research, translational medicine, and in vitro diagnostics, offering the CosMx spatial single-cell imaging platform for cell atlasing and biomarker discovery; nCounter data analysis via nSolver and ROSALIND; the nCounter Low RNA Input Kit; a Data Analysis Service; and nCounter panels and assays for gene expression across oncology, neuroscience, and cardiovascular research.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NanoString company profile →
Mirati Therapeutics Logo

Mirati Therapeutics

HQ: United States Website
  • Description: Provider of biotechnology, based at 9363 Towne Centre Dr, San Diego, CA, United States.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mirati Therapeutics company profile →
Modis Therapeutics Logo

Modis Therapeutics

HQ: United States Website
  • Description: Provider of disease-modifying therapies to patients with rare genetic diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Modis Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Sequenta

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Sequenta

2.2 - Growth funds investing in similar companies to Sequenta

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Sequenta

4.2 - Public trading comparable groups for Sequenta

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Sequenta

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Sequenta

What does Sequenta do?

Sequenta is a provider of clinical diagnostics and immune profiling tools based on a platform for understanding immune system status. Products include clonoSEQ for MRD detection and monitoring in multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; immunoSEQ for sequencing T- and B-cell receptors; T-Detect to identify recent or past infections, including COVID-19; and an Immune Medicine Platform mapping immune receptors to antigens.

Who are Sequenta's competitors?

Sequenta's competitors and similar companies include Omniome, Agena Bioscience, NanoString, Mirati Therapeutics, and Modis Therapeutics.

Where is Sequenta headquartered?

Sequenta is headquartered in United States.

How many employees does Sequenta have?

Sequenta has 1,000 employees 🔒.

When was Sequenta founded?

Sequenta was founded in 2010 🔒.

What sector and industry vertical is Sequenta in?

Sequenta is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Sequenta

Who are the top strategic acquirers in Sequenta's sector and industry

Top strategic M&A buyers and acquirers in Sequenta's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Sequenta?

Top strategic M&A buyers groups and sectors for Sequenta include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Sequenta's sector and industry vertical

Which are the top PE firms investing in Sequenta's sector and industry vertical?

Top PE firms investing in Sequenta's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Sequenta's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Sequenta's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Sequenta's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Sequenta include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Sequenta's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Sequenta?

The key public trading comparables and valuation benchmarks for Sequenta include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Sequenta for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Sequenta with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Sequenta's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Sequenta with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Sequenta's' sector and industry vertical?

Access recent funding rounds and capital raises in Sequenta's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Sequenta